The Potential Role of Interleukin-17 in the Immunopathology of Periodontal Disease
Overview
Affiliations
Background: Interleukin-17 (IL-17) is exclusively produced by activated T cells, and this cytokine can induce inflammatory responses, support immune responses (Th1), and stimulate osteoclastic bone resorption in combination with receptor activator of NF-kappaB (RANK) and RANK ligand (RANKL). These biological functions are relevant to the aetiopathogenesis of periodontitis, and thus we sought to investigate whether IL-17 is produced in periodontal lesions and to assess the relationship of gene expression between IL-17 and other cytokines, and to determine the effect of IL-17 on IL-6 production in human gingival fibroblasts (HGF).
Materials And Methods: IL-17 was detected and measured in periodontal tissues obtained as biopsy samples during periodontal surgery and in the cell-free culture supernatants cultured ex vivo, by using Western immunoblotting and enzyme-linked immunosorbent assay, respectively. IL-17 and other cytokine gene expression were investigated by the reverse transcription-polymerase chain reaction (RT-PCR) method. The contribution of IL-17 to IL-6 production by HGF was studied.
Results: IL-17 protein was moderately detected in periodontal tissues. In contrast, IL-17 mRNA was expressed only in nine of 23 periodontitis tissue samples by RT-PCR. The IL-17 mRNA-positive samples simultaneously expressed mRNAs encoding interferon (IFN)-gamma, IL-2, RANK, and RANKL, but not IL-4. IL-10 (Th2 cytokine) was detected more frequently in the samples than IFN-gamma and IL-2 (Th1 cytokine). Recombinant human IL-17 induced IL-6 production from HGF in a dose- and time-dependent fashion.
Conclusions: These results indicate that IL-17 is produced in periodontal lesions, which may be involved in Th1 modulation and enhance inflammatory reactions via gingival fibroblast-derived mediators in periodontal disease. Thus, IL-17, together with other cytokines, has a potential role in the aetiopathogenesis of periodontal disease.
Dias C, Caetano C, Costa G, Coelho A, Lemos J, de Paula D Inflammopharmacology. 2025; .
PMID: 39992590 DOI: 10.1007/s10787-025-01673-6.
Rodriguez-Montano R, Alarcon-Sanchez M, Lomeli-Martinez S, Martinez-Bugarin C, Heboyan A Immun Inflamm Dis. 2025; 13(2):e70147.
PMID: 39887950 PMC: 11783687. DOI: 10.1002/iid3.70147.
Altaca M, Cebesoy E, Kocak-Oztug N, Bingul I, Cifcibasi E BMC Oral Health. 2024; 24(1):1015.
PMID: 39215253 PMC: 11363592. DOI: 10.1186/s12903-024-04751-3.
Cytokine levels in gingival tissues as an indicator to understand periodontal disease severity.
Balu P, Balakrishna Pillai A, Mariappan V, Ramalingam S Curr Res Immunol. 2024; 5:100080.
PMID: 39026560 PMC: 11254528. DOI: 10.1016/j.crimmu.2024.100080.
Danielsen A, Massarenti L, Minculescu L, Jensen P, Hansen P, Holmstrup P J Periodontal Res. 2024; 60(2):177-188.
PMID: 38962877 PMC: 11873674. DOI: 10.1111/jre.13317.